Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
europe blog main
europe top stories
life sciences
2
×
national blog main
national top stories
abbvie
alkermes
allergan
biopharma
boston
buprenorphine
cariprazine
clinical trials
deals
duchenne
eli lilly
europe
fda
felipe jain
jess fiedorowicz
jessica jeffrey
karim calis
licensing
lumateperone
m health fairview
m&a
marc goodman
massachusetts general hospital
muscular dystrophy
national institutes of health (nih)
olanzapine
opioid
ottawa hospital
roche
samidorphan
sarepta therapeutics
steven meisel
What
fda
medicine
2
×
won
alkermes
antipsychotic
approval
benefits
betting
billion
biopharma
caveats
commonly
deal
designed
drug
duchenne
effect
favor
gain
gene
historic
offer
panel
prescribed
psyche
puts
recently
rna
roche
sarepta
second
swiss
therapeutics
therapy
treatment
vote
weighs
weight
Language
unset
Current search:
won���t
×
medicine
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal